bioMérieux Stock Forecast, Price & News

-2.00 (-1.50 %)
(As of 04/20/2021 12:00 AM ET)
Today's Range
Now: $131.25
50-Day Range
MA: $129.45
52-Week Range
Now: $131.25
Volume50 shs
Average Volume187 shs
Market Capitalization$15.53 billion
P/E Ratio50.87
Dividend YieldN/A
bioMérieux S.A. provides vitro diagnostic solutions systems for private and hospital laboratories, primarily for the diagnosis of infectious diseases. The company offers microbiology technology that identifies microorganism present in biological samples; and immunoassays technology based on antigen-antibody reaction, detects and measures infectious agents, such as bacteria, viruses, and parasites, as well as pathological markers. It also provides molecular biology for the detection of genetic sequences of deoxyribonucleic acid or ribonucleic acid; and companion diagnostic test, as well as services for clinical and industrial laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
bioMérieux logo

Industry, Sector and Symbol

Industry Private households
Year FoundedN/A



Sales & Book Value

Annual Sales$3.00 billion
Cash Flow$4.09 per share
Book Value$21.33 per share



Market Cap$15.53 billion
Next Earnings Date5/26/2021 (Estimated)
OptionableNot Optionable


bioMérieux (OTCMKTS:BMXMF) Shares Up 4%
April 14, 2021 |  americanbankingnews.com
bioMérieux - 2020 Financial Results
March 23, 2021 |  finanznachrichten.de
bioMérieux - First-Half 2020 Results
September 29, 2020 |  finanznachrichten.de
What Makes BIOMERIEUX (BMXMF) a New Buy Stock
September 10, 2020 |  finance.yahoo.com
What Makes BIOMERIEUX (BMXMF) a New Strong Buy Stock
July 27, 2020 |  finance.yahoo.com
bioMérieux Issues a €200 Million Euro PP Bond
June 29, 2020 |  finance.yahoo.com
See More Headlines


Overall MarketRank

0.50 out of 5 stars

Medical Sector

1588th out of 2,018 stocks

Private Households Industry

294th out of 377 stocks

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
-2.00 (-1.50 %)
(As of 04/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BMXMF News and Ratings via Email

Sign-up to receive the latest news and ratings for BMXMF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

bioMérieux (OTCMKTS:BMXMF) Frequently Asked Questions

Is bioMérieux a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for bioMérieux in the last twelve months. There are currently 3 sell ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" bioMérieux stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BMXMF, but not buy additional shares or sell existing shares.
View analyst ratings for bioMérieux
or view top-rated stocks.

What stocks does MarketBeat like better than bioMérieux?

Wall Street analysts have given bioMérieux a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but bioMérieux wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is bioMérieux's next earnings date?

bioMérieux is scheduled to release its next quarterly earnings announcement on Wednesday, May 26th 2021.
View our earnings forecast for bioMérieux

How has bioMérieux's stock price been impacted by COVID-19?

bioMérieux's stock was trading at $91.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BMXMF shares have increased by 43.4% and is now trading at $131.25.
View which stocks have been most impacted by COVID-19

Who are bioMérieux's key executives?

bioMérieux's management team includes the following people:
  • Mr. Alexandre Mérieux, Chairman & CEO (Age 47)
  • Mr. Frédéric Besème, Employee Director & Head of CSR (Age 65)
  • Mr. Guillaume Bouhours, Exec. VP of Purchasing and Information Systems & CFO (Age 45)
  • Mr. Pierre Boulud, Exec. VP of Clinical Operations & COO (Age 50)
  • Sylvain Morgeau, Investor Relations
  • Ms. Esther Wick, Exec. VP of Legal, IP & Compliance
  • Ms. Valérie Leyldé, Exec. VP of HR & Communications
  • Mr. François Lacoste, Exec. VP of R&D
  • Mr. Mark Miller, Exec. VP & Chief Medical Officer
  • Mr. Pierre Charbonnier, Exec. VP of Global Quality, Manufacturing & Supply Chain

Who are some of bioMérieux's key competitors?

What is bioMérieux's stock symbol?

bioMérieux trades on the OTCMKTS under the ticker symbol "BMXMF."

How do I buy shares of bioMérieux?

Shares of BMXMF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is bioMérieux's stock price today?

One share of BMXMF stock can currently be purchased for approximately $131.25.

How much money does bioMérieux make?

bioMérieux has a market capitalization of $15.53 billion and generates $3.00 billion in revenue each year. The company earns $305.54 million in net income (profit) each year or $2.58 on an earnings per share basis.

How many employees does bioMérieux have?

bioMérieux employs 12,800 workers across the globe.

What is bioMérieux's official website?

The official website for bioMérieux is www.biomerieux.com.

Where are bioMérieux's headquarters?

bioMérieux is headquartered at 376 Chemin De l`Orme, Marcy l`Etoile I0, 69280.

How can I contact bioMérieux?

bioMérieux's mailing address is 376 Chemin De l`Orme, Marcy l`Etoile I0, 69280. The company can be reached via phone at 33-4-78-87-20-00 or via email at [email protected]

This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.